利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.025 秒)

    Method of reducing biofilms
    4.
    发明授权
    Method of reducing biofilms 有权
    减少生物膜的方法

    公开(公告)号：US09534223B2

    公开(公告)日：2017-01-03

    申请号：US13643900

    申请日：2011-04-27

    申请人： Stefan Miller

    发明人： Stefan Miller

    IPC分类号： C12N9/14 ,  A61K38/16 ,  C12N15/62 ,  C12N9/36 ,  C12N9/52

    CPC分类号： A61K38/47 ,  A01N37/46 ,  A61K45/06 ,  C12N9/2462 ,  C12N9/52 ,  C12N15/62 ,  C12Y302/01017 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481

    摘要： The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said fusion protein as a diagnostic means in medicinal, food or feed or environmental diagnostic associated with bacterial biofilm.

    摘要翻译： 本发明涉及通过融合蛋白消除，减少或预防细菌生物膜的方法，所述融合蛋白包含溶解有膜或LPS破坏活性的肽的细胞内溶素，自溶蛋白或细菌素。 此外，本发明涉及用作药物的融合蛋白，特别是用于治疗或预防与细菌生物膜相关的革兰氏阴性和/或革兰氏阳性细菌感染，作为诊断手段，消毒剂或化妆品物质。 本发明还涉及与食品的细菌生物膜，食品加工设备，食品加工设备，与食品接触的表面的革兰氏阴性和/或革兰氏阳性细菌污染的去除或减少或预防， 医疗设备，医院和手术中的表面。 此外，本发明涉及所述融合蛋白作为与细菌生物膜相关的医药，食品或饲料或环境诊断中的诊断方法的用途。

    Endolysin OBPgpLYS
    10.
    发明授权
    Endolysin OBPgpLYS 有权
    内溶素OBPgpLYS

    公开(公告)号：US08846865B2

    公开(公告)日：2014-09-30

    申请号：US13390033

    申请日：2010-08-24

    申请人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

    发明人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

    IPC分类号： A61K38/43 ,  C07K14/00 ,  C12N9/26 ,  A61K38/00 ,  A61K38/04 ,  C12N9/36

    CPC分类号： C12N9/2462 ,  A01N43/50 ,  A23L3/3571 ,  A61K38/00 ,  A61K38/47 ,  C07K7/08 ,  C07K14/195 ,  C07K14/21 ,  C07K14/43518 ,  C07K2319/21 ,  C07K2319/55 ,  C12Q1/04 ,  C12Q1/34 ,  C12Y302/01017 ,  G01N2333/928

    摘要： The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

    摘要翻译： 本发明涉及具有根据SEQ ID NO：1的氨基酸序列及其片段或衍生物的多肽。 本发明还涉及包含所述多肽的融合蛋白和在N-或C-末端与所述多肽融合的另外的肽拉伸。 此外，本发明涉及编码所述多肽或融合蛋白的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及用作药物的所述多肽或融合蛋白，特别是用于治疗或预防革兰氏阴性细菌感染，作为诊断手段，作为化妆品或消毒剂。 本发明还涉及所述多肽或融合蛋白用于治疗或预防食品的食品加工设备，食品加工厂，与食品接触的表面，医疗器械的革兰氏阴性细菌污染， 在医院和手术中的表面。 此外，本发明涉及包含所述多肽或融合蛋白的药物组合物。